Article

MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: Testing Considerations and Clinical Outcomes a 3 years screening experience

2024-08-11

Abstract excerpt

<title>Abstract</title> <p>Background <italic>MET</italic> exon 14 skipping is an oncogenic driver observed in 1 to 4% of non-small cell lung cancer (NSCLC). <italic>MET</italic> exon 14 mutations affect splice sites and are highly heterogeneous which makes them difficult to detect. Because of the approval of capmatinib for patients with <italic>MET</italic> exon 14 mutated tumors and the related poor response t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: be79fd2b-e88d-594f-a29a-6aa07052878c
DOI: 10.21203/rs.3.rs-4520709/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: Testing Considerations and Clinical Outcomes a 3 years screening experienceDOI 10.21203/rs.3.rs-4520709/v1Read

MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experienceSemantic proximity Read

Pitfalls in Detecting MET Exon 14 Skipping Variants by DNA- and RNA-Based Next-Generation Sequencing Technologies in a Large Real-World Cohort and Results of the First Multinational External Quality Assessment Schemes.Semantic proximity Read

MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.Semantic proximity Read

<i>MET</i> Exon 14 Skipping in Non-Small Cell Lung CancerSemantic proximity Read

Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective.Semantic proximity Read

Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.Semantic proximity Read

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future ChallengesSemantic proximity Read

Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.Semantic proximity Read

MET Exon 14 Skipping Mutations: Essential Considerations for Current Management of Non-Small-Cell Lung Cancer.Semantic proximity Read

Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung CancerSemantic proximity Read

Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients.Semantic proximity Read

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alterationSemantic proximity Read